A Minimum 3‐Year Follow‐Up of Nivolumab‐Plus‐Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J‐ <scp>ENCORE</scp> Study

20260 citationsJournal Articlehybrid Open Access

Authors

UMIN Clinical Trials Registry: UMIN000036772 and ClinicalTrials.gov: NCT04043975.

Published in: International Journal of Urology

Volume 33, Issue 3, pp. e70400-e70400

Field-Weighted Citation Impact: 0.00